Erschienen in:
01.06.2013 | Original Article
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
verfasst von:
Juan Carlos Hernández-Boluda, Arturo Pereira, Francisco Cervantes, Montse Gómez, Eduardo Arellano-Rodrigo, Alberto Alvarez-Larrán, Francisca Ferrer-Marín, Ana Kerguelen, José Antonio Márquez, María Luisa Antelo, Carles Besses, on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Erschienen in:
Annals of Hematology
|
Ausgabe 6/2013
Einloggen, um Zugang zu erhalten
Abstract
This study investigates whether the response criteria proposed by the European LeukemiaNet (ELN) to evaluate cytoreductive therapies in essential thrombocythemia (ET) correlate with clinically relevant outcomes in patients receiving anagrelide. We evaluated 154 ET patients treated with anagrelide (upfront in 87) for a median of 2.9 years. Complete response (CR), partial response, and no response were observed in 56, 30.5, and 13.5 % patients, respectively. Only 38 patients (25 %) achieved a sustained CR. Overall, the aggregated time on CR and without CR was 200.1 and 333.6 person-years, respectively. The incidence rate of thrombosis and hemorrhage was independent of the CR status. The only factor associated with shorter survival after anagrelide start was the patient's age, whereas achieving a CR with anagrelide had no predictive value for subsequent survival. In conclusion, CR according to the ELN definition is not associated with any measurable clinical benefit in ET patients treated with anagrelide.